Christopher Kemp

Oncology · 2013–2017

A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Christopher Kemp trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Nitiss

Papers from Christopher Kemp's perspective

Ordered by how strongly the researchers Christopher Kemp trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Identification of the molecular basis of doxorubicin-induced cardiotoxicity (Nature Medicine)
  2. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. (Cancer Discovery)
  3. How to improve R&D productivity: the pharmaceutical industry's grand challenge
  4. A Landscape of Pharmacogenomic Interactions in Cancer (Cell)
  5. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity (Nature)
  6. Doxorubicin pathways: pharmacodynamics and adverse effects (Pharmacogenetics & Genomics)
  7. Trial Watch: Phase II and Phase III attrition rates 2011–2012 (Nature reviews. Drug discovery)
  8. Targeting DNA topoisomerase II in cancer chemotherapy (Nature Reviews. Cancer)
  9. Prospective derivation of a Living Organoid Biobank of colorectal cancer patients (Cell)
  10. Doxorubicin: the good, the bad and the ugly effect. (Current Medicinal Chemistry)

Their papers